Oncology Today with Dr Neil Love — Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition
Hematologic Oncology Update
00:00
The Efficacy Advantage of the Dell 17P Drug
B2K occupancy at 90% or greater in the lymph node with these various doses. The PK data would suggest that the dose level in the plasma remains well above the IC50 throughout the entire dosing interval. So, you know, it's constantly inhibiting B2K. And if you've got drug around, you can inhibit it and knock it out. Whereas with other agents, it quickly drops below that IC50.
Transcript
Play full episode
